<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632371</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE NO. S00112</org_study_id>
    <secondary_id>CIV-12-05-006401</secondary_id>
    <nct_id>NCT01632371</nct_id>
  </id_info>
  <brief_title>Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4</brief_title>
  <acronym>ISAR-DESIRE 4</acronym>
  <official_title>ISAR-DESIRE 4: Randomized Trial Of Scoring Balloon in Patients With Restenosis in &quot;Limus&quot;-Eluting Coronary Stents Undergoing Angioplasty With Paclitaxel-Coated Balloon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether scoring balloon (SCB) plus paclitaxel-coated&#xD;
      balloon (PCB) is superior to PCB alone for the treatment of restenosis within &quot;limus&quot;-eluting&#xD;
      stents (LES)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal treatment of in-BMS-restenosis seems to be implantation of a DES which is&#xD;
      supported by a large body of evidence. Nevertheless, several recent published studies have&#xD;
      shown a substantial reduction in late lumen loss and angiographic restenosis using&#xD;
      paclitaxel-coated balloons (PCB) for restenotic lesions. Given the increased world-wide use&#xD;
      of DES and the use of DES in increasingly complex coronary disease patterns, the number of&#xD;
      patients presenting with restenosis after DES implantation will further increase in the&#xD;
      coming decade.&#xD;
&#xD;
      Data regarding the optimal treatment of in-DES-restenosis are very limited: Implanting a new&#xD;
      DES for in-DES-restenosis has been reported to associate with repeat restenosis rates as high&#xD;
      as 20%. In addition, an increased risk of stent thrombosis has been associated with complex&#xD;
      stenting and with additional DES implantation. Thus, for lesions which develop restenosis&#xD;
      after LES implantation, the optimal treatment strategy remains unknown.&#xD;
&#xD;
      Few results on small sample-size populations have been reported in patients treated with&#xD;
      scoring or cutting balloon (SCB) technology for treatment of BMS restenosis as compared to&#xD;
      plain balloon angioplasty. Moreover, the efficacy of SCB angioplasty in DES restenosis has&#xD;
      not been adequately addressed. Furthermore, the potential additive benefit of SCB angioplasty&#xD;
      in patients undergoing PCB therapy remains to be elucidated. The hypothesis behind this&#xD;
      concept is that the application of SCB prior to deployment of PCB may increase the&#xD;
      bioavailability of paclitaxel within the restenotic tissue, and therefore may increase the&#xD;
      efficacy of PCB. There are numerous preclinical studies to support this hypothesis, which&#xD;
      show that lesion preparation is an important pre-requisite for the effectiveness of PCB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment percent diameter stenosis</measure>
    <time_frame>6-8 months</time_frame>
    <description>In-segment percent diameter stenosis (%DS) at 6-8 month follow-up angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent late lumen loss</measure>
    <time_frame>6-8 months</time_frame>
    <description>The difference between minimal lumen diameter post-procedure and minimal lumen diameter at follow-up angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment binary angiographic restenosis</measure>
    <time_frame>6-8 month</time_frame>
    <description>diameter stenosis ≥50% in the in-segment area (including the interventional area as well as 5 mm margins proximal and distal) at follow-up angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or myocardial infarction</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Combined incidence of death or myocardial infarction at one and two year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Need for target lesion revascularization (TLR), defined as any revascularization procedure involving the target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia at one and two year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion thrombosis</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Incidence of target lesion thrombosis at one and two years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT tissue characterization</measure>
    <time_frame>6-8 months</time_frame>
    <description>Tissue characterization following application of SCB and PCB using OCT at 6 -8 months follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Restenosis</condition>
  <condition>Stable Angina Pectoris</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Paclitaxel Eluting Balloon + Scoring Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel Eluting Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel Eluting Balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel Eluting Balloon + Scoring Balloon</intervention_name>
    <description>Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy</description>
    <arm_group_label>Paclitaxel Eluting Balloon + Scoring Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel Eluting Balloon</intervention_name>
    <description>Standard balloon lesion predilation; paclitaxel-eluting balloon therapy</description>
    <arm_group_label>Paclitaxel Eluting Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ischemic symptoms or evidence of myocardial ischemia in the presence of&#xD;
             ≥ 50% restenosis after prior implantation of LES in native coronary vessels.&#xD;
&#xD;
          -  Written, informed consent by the patient or her/his legally-authorized representative&#xD;
             for participation in the study.&#xD;
&#xD;
          -  In women with childbearing potential a negative pregnancy test is mandatory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Acute ST-elevation myocardial infarction within 48 hours from symptom onset.&#xD;
&#xD;
          -  Malignancies or other comorbid conditions (for example severe liver, renal and&#xD;
             pancreatic disease) with life expectancy less than 12 months or that may result in&#xD;
             protocol non-compliance.&#xD;
&#xD;
          -  Severe renal insufficiency (glomerular filtration rate ≤ 30 ml/min)&#xD;
&#xD;
          -  Contraindications to antiplatelet therapy, paclitaxel, stainless steel, cobalt, chrome&#xD;
&#xD;
          -  Therapy including Lovastatin, Ciclosporin, Terfenadine, Midazolam, or Ondansetron&#xD;
&#xD;
          -  Pregnancy (present, suspected or planned) or positive pregnancy test.&#xD;
&#xD;
          -  Previous enrollment in this trial.&#xD;
&#xD;
          -  Patient's inability to fully comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Byrne, MB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1. Med. Klinik am Klinikum rechts der Isar der TU Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2012</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In-stent Restenosis</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <keyword>Paclitaxel Coated Balloon</keyword>
  <keyword>Scoring Balloon</keyword>
  <keyword>Cutting Balloon</keyword>
  <keyword>Angiographic follow-up</keyword>
  <keyword>Optical coherence tomography (OCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

